Prime Medicine

PRME on Nasdaq. Prime Medicine develops gene editing medicines for patients with genetic diseases. Market value $582m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-24.7%low

For every $100 of what the whole company costs, it produced $-24.71 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-176.8%five-year median

Each dollar kept in the business earns -177 cents a year. Above 10 is good.

Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$3.50 a share, 31% above its 1-year low

Over the past year the price has ranged from $2.67 to $6.85.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.2
-0.1
-0.2
-0.2
202220232024202512 monthsto Jun '26
Revenue
$0$0$3m$5m
Operating margin
n/an/a-6787.4%-4498.1%
Debt to equity
0.000.000.000.00
Shares outstanding
0.10bn0.13bn0.18bn0.18bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.00× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 86% more shares since 2022

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $42 million, compared with a loss of $53 million a year ago.
  • Over the past 12 months it spent $157 million more cash than it brought in, compared with $107 million a year earlier.
  • 37% more shares than a year ago. Each share owns a bit less of the company.
  • It has $47 million more cash than debt, down from $54 million a year ago.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$209,000
December 2024$2m
March 2025$1m
June 2025$1m
September 2025$1m
December 2025$838,000
March 2026Not reported
June 2026Not reported
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$53m
December 2024-$42m
March 2025-$52m
June 2025-$53m
September 2025-$51m
December 2025-$46m
March 2026-$49m
June 2026-$42m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
3 March 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

None of the long-term investors we follow own it. 187 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

  • Alphabet Holdings LLC
    Passive investor
    at least 12.3%
    (filed with 8 related holders)
    Since 30 September 2025
  • ARCH Venture Fund X, L.P.
    Passive investor
    at least 10.4%
    (filed with 11 related holders)
    Since 7 August 2025
  • Newpath Partners, L.P.
    Passive investor
    at least 4.7%
    (filed with 2 related holders)
    Since 31 December 2024
  • FMR LLC
    Passive investor
    at least 3.8%
    (filed with 1 related holder)
    Since 30 September 2025
  • Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Prime Medicine’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 3 Mar 2026, plus the 10-Q filed 6 Aug 2026 and 5 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “Because certain elements of management’s plans to mitigate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern are outside of the Company’s control, including the ability to raise capital through an equity or other financing, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors.”
    Show the full paragraph
    In accordance with Accounting Standards Codification, or ASC, 205-40, Going Concern , or ASC 205-40, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date on which this Quarterly Report on Form 10-Q is filed. Based on the Company's cash, cash equivalents, and short-term investments as of June 30, 2026, the Company's current and forecasted level of operations, and its forecasted cash flows, the Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management plans to provide for the Company’s capital requirements through financing or other transactions, and selling shares under the Company's “at the market offering” program. There can be no assurance that the Company will be able to raise additional capital to fund operations with terms acceptable to the Company, or at all. Because certain elements of management’s plans to mitigate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern are outside of the Company’s control, including the ability to raise capital through an equity or other financing, those elements cannot be considered probable according to ASC 205-40, and therefore cannot be considered in the evaluation of mitigating factors. As a result, management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.

    From the 10-Q filed 6 August 2026, Part I, Item 1. Financial Statements. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.